Safe and cost-effective control of post-transplantation recurrence of hepatitis B

Hepatology Research

Volumn 45, Issue 1, 2015, Pages 38-47

  Takaki, Akinobu ^a   Yagi, Takahito ^a   Yamamoto, Kazuhide ^a  

^a OKAYAMA UNIVERSITY   (Japan)

Author keywords

Antiviral agent; Hepatitis B; Hepatitis B immunoglobulin; Hepatitis B vaccine; Liver transplantation; Prophylaxis

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; EMTRICITABINE; ENTECAVIR; HEPATITIS B ANTIBODY; HEPATITIS B SURFACE ANTIGEN; HEPATITIS B VACCINE; LAMIVUDINE; NUCLEOSIDE ANALOG; NUCLEOTIDE DERIVATIVE; TELBIVUDINE; TENOFOVIR; VIRUS DNA;

ADD ON THERAPY; ANTIBODY TITER; ANTIVIRAL RESISTANCE; CHRONIC DRUG ADMINISTRATION; CLINICAL PROTOCOL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; HEPATITIS B; HUMAN; IMMUNOLOGICAL TOLERANCE; INFECTION CONTROL; INFECTION PREVENTION; LIVER CIRRHOSIS; LIVER TRANSPLANTATION; LOW DRUG DOSE; PRIORITY JOURNAL; RECURRENT VIRUS INFECTION; REVIEW; SYSTEMATIC REVIEW; TREATMENT WITHDRAWAL; VACCINATION; VIRUS REACTIVATION;

EID: 84921057426     PISSN: 13866346     EISSN: 1872034X     Source Type: Journal    
DOI: 10.1111/hepr.12368     Document Type: Review

References (68)

1. Todo S, Demetris AJ, Van Thiel D, Teperman L, Fung JJ, Starzl TE. Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology 1991; 13: 619-626.
2. Samuel D, Muller R, Alexander G etal. Liver transplantation in European patients with the hepatitis B surface antigen. N Engl J Med 1993; 329: 1842-1847.
3. Grellier L, Mutimer D, Ahmed M etal. Lamivudine prophylaxis against reinfection in liver transplantation for hepatitis B cirrhosis. Lancet 1996; 348: 1212-1215.
4. Perrillo R, Rakela J, Dienstag J etal. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 1999; 29: 1581-1586.
5. Markowitz JS, Martin P, Conrad AJ etal. Prophylaxis against hepatitis B recurrence following liver transplantation using combination lamivudine and hepatitis B immune globulin. Hepatology 1998; 28: 585-589.
6. Schilling R, Ijaz S, Davidoff M etal. Endocytosis of hepatitis B immune globulin into hepatocytes inhibits the secretion of hepatitis B virus surface antigen and virions. J Virol 2003; 77: 8882-8892.
7. Yasunaka T, Takaki A, Yagi T etal. Serum hepatitis B virus DNA before liver transplantation correlates with HBV reinfection rate even under successful low-dose hepatitis B immunoglobulin prophylaxis. Hepatol Int 2011; [Epub ahead of print].
8. Neumann AU, Phillips S, Levine I etal. Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells. Hepatology 2010; 52: 875-885.
9. Villet S, Billioud G, Pichoud C etal. In vitro characterization of viral fitness of therapy-resistant hepatitis B variants. Gastroenterology 2009; 136: 168-176.
10. Johnson PJ, Wansbrough-Jones MH, Portmann B etal. Familial HBsAg-positive hepatoma: treatment with orthotopic liver transplantation and specific immunoglobulin. Br Med J 1978; 1: 216.
11. Ben-Ari Z, Mor E, Shapira Z, Tur-Kaspa R. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation. Liver Transpl 2001; 7: 113-117.
12. Fontana RJ, Hann HW, Wright T etal. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation. Liver Transpl 2001; 7: 504-510.
13. Dumortier J, Chevallier P, Scoazec JY, Berger F, Boillot O. Combined lamivudine and hepatitis B immunoglobulin for the prevention of hepatitis B recurrence after liver transplantation: long-term results. Am J Transplant 2003; 3: 999-1002.
14. Yoshida EM, Erb SR, Partovi N etal. Liver transplantation for chronic hepatitis B infection with the use of combination lamivudine and low-dose hepatitis B immune globulin. Liver Transpl Surg 1999; 5: 520-525.
15. Marzano A, Salizzoni M, Debernardi-Venon W etal. Prevention of hepatitis B virus recurrence after liver transplantation in cirrhotic patients treated with lamivudine and passive immunoprophylaxis. J Hepatol 2001; 34: 903-910.
16. Roche B, Samuel D. Evolving strategies to prevent HBV recurrence. Liver Transpl 2004; 10: S74-85.
17. Yao FY, Osorio RW, Roberts JP etal. Intramuscular hepatitis B immune globulin combined with lamivudine for prophylaxis against hepatitis B recurrence after liver transplantation. Liver Transpl Surg 1999; 5: 491-496.
18. Gane EJ, Angus PW, Strasser S etal. Lamivudine plus low-dose hepatitis B immunoglobulin to prevent recurrent hepatitis B following liver transplantation. Gastroenterology 2007; 132: 931-937.
19. Rosenau J, Bahr MJ, Tillmann HL etal. Lamivudine and low-dose hepatitis B immune globulin for prophylaxis of hepatitis B reinfection after liver transplantation possible role of mutations in the YMDD motif prior to transplantation as a risk factor for reinfection. J Hepatol 2001; 34: 895-902.
20. Jiang L, Yan L, Li B etal. Prophylaxis against hepatitis B recurrence posttransplantation using lamivudine and individualized low-dose hepatitis B immunoglobulin. Am J Transplant 2010; 10: 1861-1869.
21. Di Paolo D, Tisone G, Piccolo P, Lenci I, Zazza S, Angelico M. Low-dose hepatitis B immunoglobulin given "on demand" in combination with lamivudine: a highly cost-effective approach to prevent recurrent hepatitis B virus infection in the long-term follow-up after liver transplantation. Transplantation 2004; 77: 1203-1208.
22. Takaki A, Yagi T, Iwasaki Y etal. Short-term high-dose followed by long-term low-dose hepatitis B immunoglobulin and lamivudine therapy prevented recurrent hepatitis B after liver transplantation. Transplantation 2007; 83: 231-233.
23. Neff GW, O'Brien CB, Nery J etal. Outcomes in liver transplant recipients with hepatitis B virus: resistance and recurrence patterns from a large transplant center over the last decade. Liver Transpl 2004; 10: 1372-1378.
24. Buti M, Mas A, Prieto M etal. A randomized study comparing lamivudine monotherapy after a short course of hepatitis B immune globulin (HBIg) and lamivudine with long-term lamivudine plus HBIg in the prevention of hepatitis B virus recurrence after liver transplantation. J Hepatol 2003; 38: 811-817.
25. Marzano A, Lampertico P, Mazzaferro V etal. Prophylaxis of hepatitis B virus recurrence after liver transplantation in carriers of lamivudine-resistant mutants. Liver Transpl 2005; 11: 532-538.
26. Angus PW, Patterson SJ, Strasser SI, McCaughan GW, Gane E. A randomized study of adefovir dipivoxil in place of HBIG in combination with lamivudine as post-liver transplantation hepatitis B prophylaxis. Hepatology 2008; 48: 1460-1466.
27. Gane EJ, Patterson S, Strasser SI, McCaughan GW, Angus PW. Combination of lamivudine and adefovir without hepatitis B immune globulin is safe and effective prophylaxis against hepatitis B virus recurrence in hepatitis B surface antigen-positive liver transplant candidates. Liver Transpl 2013; 19: 268-274.
28. Cholongitas E, Vasiliadis T, Antoniadis N, Goulis I, Papanikolaou V, Akriviadis E. Hepatitis B prophylaxis post liver transplantation with newer nucleos(t)ide analogues after hepatitis B immunoglobulin discontinuation. Transpl Infect Dis 2012; 14: 479-487.
29. Cai CJ, Lu MQ, Chen YH, Zhao H, Li MR, Chen GH. Clinical study on prevention of HBV re-infection by entecavir after liver transplantation. Clin Transplant 2012; 26: 208-215.
30. Ueda Y, Marusawa H, Kaido T etal. Efficacy and safety of prophylaxis with entecavir and hepatitis B immunoglobulin in preventing hepatitis B recurrence after living-donor liver transplantation. Hepatol Res 2013; 43: 67-71.
31. Gao YJ, Zhang M, Jin B etal. A clinical-pathological analysis of hepatitis B virus recurrence after liver transplantation in Chinese patients. J Gastroenterol Hepatol 2014; 29: 554-560.
32. Perrillo R, Buti M, Durand F etal. Entecavir and hepatitis B immune globulin in patients undergoing liver transplantation for chronic hepatitis B. Liver Transpl 2013; 19: 887-895.
33. Yi NJ, Choi JY, Suh KS etal. Post-transplantation sequential entecavir monotherapy following 1-year combination therapy with hepatitis B immunoglobulin. J Gastroenterol 2013; 48: 1401-1410.
34. Stravitz RT, Shiffman ML, Kimmel M etal. Substitution of tenofovir/emtricitabine for Hepatitis B immune globulin prevents recurrence of Hepatitis B after liver transplantation. Liver Int 2012; 32: 1138-1145.
35. Wesdorp DJ, Knoester M, Braat AE etal. Nucleoside plus nucleotide analogs and cessation of hepatitis B immunoglobulin after liver transplantation in chronic hepatitis B is safe and effective. J Clin Virol 2013; 58: 67-73.
36. Fung J, Cheung C, Chan SC etal. Entecavir monotherapy is effective in suppressing hepatitis B virus after liver transplantation. Gastroenterology 2011; 141: 1212-1219.
37. Wadhawan M, Gupta S, Goyal N, Taneja S, Kumar A. Living related liver transplantation for hepatitis B-related liver disease without hepatitis B immune globulin prophylaxis. Liver Transpl 2013; 19: 1030-1035.
38. Chao DC, Hu KQ. Update on rescue therapies in patients with lamivudine-resistant chronic hepatitis B. Drug Des Devel Ther 2013; 7: 777-788.
39. Kitrinos KM, Corsa A, Liu Y etal. No detectable resistance to tenofovir disoproxil fumarate after 6 years of therapy in patients with chronic hepatitis B. Hepatology 2014; 59: 434-442.
40. Tenney DJ, Rose RE, Baldick CJ etal. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology 2009; 49: 1503-1514.
41. Lenci I, Tisone G, Di Paolo D etal. Safety of complete and sustained prophylaxis withdrawal in patients liver-transplanted for HBV-related cirrhosis at low risk of HBV recurrence. J Hepatol 2011; 55: 587-593.
42. Kimura T, Rokuhara A, Sakamoto Y etal. Sensitive enzyme immunoassay for hepatitis B virus core-related antigens and their correlation to virus load. J Clin Microbiol 2002; 40: 439-445.
43. Matsuzaki T, Tatsuki I, Otani M etal. Significance of hepatitis B virus core-related antigen and covalently closed circular DNA levels as markers of hepatitis B virus re-infection after liver transplantation. J Gastroenterol Hepatol 2013; 28: 1217-1222.
44. DiMiceli L, Pool V, Kelso JM, Shadomy SV, Iskander J, Team VAERS. Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 2006; 24: 703-707.
45. Zhou W, Pool V, Iskander JK etal. Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS) - United States, 1991-2001. Morbidity and mortality weekly report Surveillance summaries. 2003 Jan 24; 52: 1-24.
46. Rosenau J, Hooman N, Rifai K etal. Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: failure of humoral and cellular immune response. Transpl Int 2006; 19: 828-833.
47. Ishigami M, Kamei H, Nakamura T etal. Different effect of HBV vaccine after liver transplantation between chronic HBV carriers and non-HBV patients who received HBcAb-positive grafts. J Gastroenterol 2011; 46: 367-377.
48. Bauer T, Gunther M, Bienzle U, Neuhaus R, Jilg W. Vaccination against hepatitis B in liver transplant recipients: pilot analysis of cellular immune response shows evidence of HBsAg-specific regulatory T cells. Liver Transpl 2007; 13: 434-442.
49. Starkel P, Stoffel M, Lerut J, Horsmans Y. Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transpl 2005; 11: 1228-1234.
50. Yamashiki N, Sugawara Y, Tamura S etal. Double-dose double-phase use of second generation hepatitis B virus vaccine in patients after living donor liver transplantation: not an effective measure in transplant recipients. Hepatol Res 2009; 39: 7-13.
51. Tahara H, Tanaka Y, Ishiyama K etal. Successful hepatitis B vaccination in liver transplant recipients with donor-specific hyporesponsiveness. Transpl Int 2009; 22: 805-813.
52. Di Paolo D, Lenci I, Cerocchi C etal. One-year vaccination against hepatitis B virus with a MPL-vaccine in liver transplant patients for HBV-related cirrhosis. Transpl Int 2010; 23: 1105-1112.
53. Takaki A, Yagi T, Yasunaka T etal. Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation? J Gastroenterol 2013; 48: 1373-1383.
54. Feng L, Niu Y, Chen H etal. Immunogenicity of different hepatitis B virus vaccination schedules in liver transplant recipients. Hepatol Res 2013; 43: 495-501.
55. Sanchez-Fueyo A, Rimola A, Grande L etal. Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: a new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501.
56. Lo CM, Liu CL, Chan SC, Lau GK, Fan ST. Failure of hepatitis B vaccination in patients receiving lamivudine prophylaxis after liver transplantation for chronic hepatitis B. J Hepatol 2005; 43: 283-287.
57. Karasu Z, Ozacar T, Akarca U etal. HBV vaccination in liver transplant recipients: not an effective strategy in the prophylaxis of HBV recurrence. J Viral Hepat 2005; 12: 212-215.
58. Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-509.
59. Di Paolo D, Lenci I, Trinito MO etal. Extended double-dosage HBV vaccination after liver transplantation is ineffective, in the absence of lamivudine and prior wash-out of human Hepatitis B immunoglobulins. Dig Liver Dis 2006; 38: 749-754.
60. Zhang J, Zhou L, Zheng SS. Clinical management of hepatitis B virus infection correlated with liver transplantation. Hepatobiliary Pancreat Dis Int 2010; 9: 15-21.
61. Kennedy PT, Sandalova E, Jo J etal. Preserved T-cell function in children and young adults with immune-tolerant chronic hepatitis B. Gastroenterology 2012; 143: 637-645.
62. Rosenau J, Hooman N, Hadem J etal. Failure of hepatitis B vaccination with conventional HBsAg vaccine in patients with continuous HBIG prophylaxis after liver transplantation. Liver Transpl 2007; 13: 367-373.
63. Wursthorn K, Wedemeyer H, Manns MP. Managing HBV in patients with impaired immunity. Gut 2010; 59: 1430-1445.
64. Schumann A, Lindemann M, Valentin-Gamazo C etal. Adoptive immune transfer of hepatitis B virus specific immunity from immunized living liver donors to liver recipients. Transplantation 2009; 87: 103-111.
65. Luo Y, Lo CM, Cheung CK, Lau GK, Fan ST, Wong J. Identification of hepatitis B virus-specific lymphocytes in human liver grafts from HBV-immune donors. Liver Transpl 2007; 13: 71-79.
66. Crispe IN. The liver as a lymphoid organ. Annu Rev Immunol 2009; 27: 147-163.
67. Ueda Y, Marusawa H, Egawa H etal. De novo activation of HBV with escape mutations from hepatitis B surface antibody after living donor liver transplantation. Antivir Ther 2011; 16: 479-487.
68. Lai MW, Lin TY, Tsao KC etal. Increased seroprevalence of HBV DNA with mutations in the s gene among individuals greater than 18 years old after complete vaccination. Gastroenterology 2012; 143: 400-407.